Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in behcet disease

Retina

Volumn 32, Issue 7, 2012, Pages 1395-1402

  Bae, Jeong Hun ^a,b   Lee, Sung Chul ^b  

^a School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Behcet disease; cytokine; methotrexate; retinal vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; BEHCET DISEASE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEOMICS; RETINA DETACHMENT; RETINA DISEASE; RETINA VASCULITIS; SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADOLESCENT; ADULT; AQUEOUS HUMOR; BEHCET SYNDROME; CYTOKINES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; METHOTREXATE; MIDDLE AGED; RETINAL VASCULITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84862904303     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31823496a3     Document Type: Article

References (30)

1. Deuter CM, Kotter I, Wallace GR, et al. Behcet's disease: ocular effects and treatment. Prog Retin Eye Res 2008;27: 111-136.
2. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005;89:806-808. (Pubitemid 40904797)
3. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108:1134-1139. (Pubitemid 32500033)
4. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intra-vitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-1156. (Pubitemid 27387951)
5. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716. (Pubitemid 35012013)
6. Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142:883-885. (Pubitemid 44584144)
7. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116:797-801.
8. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516. (Pubitemid 41224845)
9. Akdeniz N, Esrefoglu M, Keles MS, et al. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 2004;33:596-599. (Pubitemid 39626965)
10. Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of muco-cutaneous lesions of Behcet's disease. Arthritis Rheum 2004; 50:2291-2295. (Pubitemid 38924408)
11. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. Int J Dermatol 2003;42:870-875. (Pubitemid 37441452)
12. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol 2006;142: 429-434.
13. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008;92:383-388. (Pubitemid 351363536)
14. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682. (Pubitemid 24006532)
15. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-273. (Pubitemid 34716307)
16. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153: 4159-4168. (Pubitemid 24322583)
17. Constantin A, Loubet-Lescoulie P, Lambert N, et al. Antiin-flammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998;41:48-57. (Pubitemid 28041922)
18. Hoekzema R, Verhagen C, van Haren M, Kijlstra A. Endotox-in-induced uveitis in the rat. The significance of intraocular interleukin-6. Invest Ophthalmol Vis Sci 1992;33:532-539.
19. Yoshida A, Yoshida S, Khalil AK, et al. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovasculariza-tion. Invest Ophthalmol Vis Sci 1998;39:1097-1106. (Pubitemid 28247343)
20. Aki T, Karincaoglu Y, Seyhan M, Batcioglu K. Serum substance P and calcitonin gene-related peptide levels in Behcet's disease and their association with disease activity. Clin Exp Dermatol 2006;31:583-587. (Pubitemid 43806597)
21. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005;105:1405-1407. (Pubitemid 40223654)
22. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-77. (Pubitemid 34076505)
23. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115:1750-1755, 1755.e1.
24. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-796. (Pubitemid 33031303)
25. Wakai A, Wang JH, Winter DC, et al. Adenosine inhibits neutrophil vascular endothelial growth factor release and trans-endothelial migration via A2B receptor activation. Shock 2001;15:297-301. (Pubitemid 33596722)
26. Yamada M, Kim S, Egashira K, et al. Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003;23:1996-2001. (Pubitemid 37433191)
27. Bouma MG, van den Wildenberg FA, Buurman WA. Adeno-sine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996;270(pt 1):C522-C529.
28. El-Asrar AM, Herbort CP, Tabbara KF. A clinical approach to the diagnosis of retinal vasculitis. Int Ophthalmol 2010;30: 149-173.
29. Hughes EH, Dick AD. The pathology and pathogenesis of retinal vasculitis. Neuropathol Appl Neurobiol 2003;29:325-340. (Pubitemid 36960334)
30. Deng SX, Penland S, Gupta S, et al. Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model. Invest Ophthalmol Vis Sci 2006;47:1516-1521. (Pubitemid 46780760)